Evolving gene therapy approaches for osteosarcoma using viral vectors: Review

Witlox, M.A.; Lamfers, Martine L.M.; Wuisman, P.; Curiel, David T.; Siegal, Gene P.

doi:10.1016/j.bone.2006.10.017

Cited by 40 publications

(22 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the transfection efficiency of the cationic liposome is relatively low compared to virus vector. Viral vectors have been the popular transgenic tool because of their higher efficiency [23,29]. Madry et al used recombinant adeno-associated viruses containing the reporter gene lacZ to transfer into the lapine and human meniscal cells in vitro and into lapine meniscal defects in vivo [18].…”

Section: Discussionmentioning

confidence: 99%

Treating Human Meniscal Fibrochondrocytes with hIGF-1 Gene by Liposome

Zhang

Leng

Wang

et al. 2009

Clin Orthop Relat Res

View full text Add to dashboard Cite

The menisci are intraarticular fibrocartilaginous structures essential to the normal function of the knee that lack the ability to self-repair. Human meniscal fibrochondrocytes may respond to beneficial genes like human insulin growth factor-1 (hIGF-1) and the meniscal cell may be a feasible donor for gene therapy. To explore this possibility, we amplified the hIGF-1 gene sequence in full length and cloned it into a bicistronic plasmid. This gene was then transfected into cultured human meniscal fibrochondrocytes by the liposome FuGene 6. Green fluorescence was expressed in part of the cells 6 hours after transfection and increased gradually, with a peak concentration of the hIGF-1 in the supernatants to 22.68 ng/mL 56 hours after transfection. Phenotypes of some cells changed and the proliferation accelerated after transfection. Flow cytometry analysis demonstrated upregulation of cell numbers in the G2 and S stages after hIGF-1 gene introduction. We conclude the hIGF-1 gene can be transfected into the human meniscal cell efficiently by liposome and it causes accelerated proliferation and differentiation. Within 10 days after transfection, the cytokine appears to be secreted into supernatants with the bioactivity and promotes the proliferation of the NIH 3T3 cell line.

show abstract

Section: Discussionmentioning

confidence: 99%

Treating Human Meniscal Fibrochondrocytes with hIGF-1 Gene by Liposome

Zhang

Leng

Wang

et al. 2009

Clin Orthop Relat Res

View full text Add to dashboard Cite

show abstract

“…However, viral gene delivery has significant drawbacks restricting clinical use including immunogenicity, toxicity and technical challenges for large scale production [18][19][20].…”

Section: Accepted M Manuscriptmentioning

confidence: 99%

Part I: Minicircle vector technology limits DNA size restrictions on ex vivo gene delivery using nanoparticle vectors: Overcoming a translational barrier in neural stem cell therapy

Fernandes

Chari

2016

Journal of Controlled Release

View full text Add to dashboard Cite

Please cite this article as: Alinda R. Fernandes, Divya M. Chari, Part I: Minicircle vector technology limits DNA size restrictions on ex vivo gene delivery using nanoparticle vectors: Overcoming a translational barrier in neural stem cell therapy, Journal of Controlled Release (2016Release ( ), doi: 10.1016Release ( /j.jconrel.2016 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT

show abstract

“…Viral systems have advantages such as constant expression and expression of therapeutic genes (Sullivan, 2003). However, there are some limitations that restrict the use of these systems, which particularly include the use of viruses in production, immunogenicity, toxicity and lack of optimization in large-scale production (Witlox et al, 2007) (Figure 1). Gene therapy strategies; mutation compensation, suicide gene therapy and immunopotentiation (Witlox et al, 2007).…”

Section: Gene Delivery Systemsmentioning

confidence: 99%